Selected data models

You must log in to select data models for download or further analysis.

2 Search results.
Relevance Rating New first Old first

Oral Topotecan as Radiosensitizing Agent in Patients with Rectal Cancer; NCT00158886 - Serious Adverse Experiences (SAE)

- 8/20/19 - 1 form, 6 itemgroups, 31 items, 1 language
Itemgroups: Administrative documentation, Serious Adverse Event, Serious Adverse Event. Laboratory test finding, Serious Adverse Event, Comment, Serious Adverse Event, Randomization, Serious Adverse Event, Investigator Signature
Study ID: 104864/517 Clinical Study ID: 104864/517 Study Title: A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00158886 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Topotecan + Radiation therapy Trade Name: N/A Study Indication: Rectal Cancer, Carcinoma, Renal Cell

Oral Topotecan as Radiosensitizing Agent in Patients with Rectal Cancer; NCT00158886 - Adverse Experiences (Non-serious)

- 8/20/19 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Administrative documentation, Non-Serious Adverse Event
Study ID: 104864/517 Clinical Study ID: 104864/517 Study Title: A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00158886 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Topotecan + Radiation therapy Trade Name: N/A Study Indication: Rectal Cancer, Carcinoma, Renal Cell

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial